Patents Examined by Jennifer E. Graser
  • Patent number: 10688171
    Abstract: Disclosed herein is a Chlamydia-activated B cell (CAB) platform. Also disclosed is a method of enhancing a population of B cells, comprising exposing said B cells to Chlamydia spp. under conditions suitable to enhance the population of B cells, such that expansion and differentiation of said B cells takes place, and said B cells are exposed or crosslinked to an antigen. Also disclosed are methods of producing said CABs, and treating a subject in need thereof with said CABs.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: June 23, 2020
    Assignee: Ohio State Innovation Foundation
    Inventors: Thomas Cherpes, Rodolfo Vicetti Miguel
  • Patent number: 10675249
    Abstract: The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: June 9, 2020
    Assignee: Orbis Health Solutions, LLC
    Inventor: Thomas E. Wagner
  • Patent number: 10668140
    Abstract: Described are non-toxigenic Clostridium difficile strains and spores. Also described are vaccines comprising the Clostridium difficile spores. Further described are methods of preventing or treating a Clostridium difficile infection in a subject in need thereof.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 2, 2020
    Assignees: University of South Floirida, Trustees of Tufts College
    Inventors: Xingmin Sun, Abraham Sonenshein
  • Patent number: 10667522
    Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one further biological control agent selected from particular microorganisms disclosed herein and/or a mutant of a specific strain of a microorganism disclosed herein having all identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: June 2, 2020
    Assignee: BASF SE
    Inventors: Damian Curtis, Brian Thompson
  • Patent number: 10670598
    Abstract: The present invention discloses a preparation method of Cryptococcus neoformans capsular polysaccharide GXM as well as a GXM antigen immunoassay kit and an application thereof. The preparation method of the Cryptococcus neoformans capsular polysaccharide GXM effectively avoids the use of a toxic chemical reagent, ensures safety of operators, and also avoids environmental pollution, has high specificity, and can prepare a high-purity Cryptococcus neoformans capsular polysaccharide while simplifying a preparation process. The GXM antigen immunoassay kit adopts a competition method, has good sensitivity, specificity, repeatability and stability, has high recovery rate of a target compound and may provide more accurate and reliable inspection results. The kit is simple and feasible in use and operation, rapid and sensitive in detection and low in price and provides an effective tool for clinical detection of GXM.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 2, 2020
    Inventors: Jie Peng, Dongdong Shi, Ning Li, Yan Su, Zeqi Zhou
  • Patent number: 10663460
    Abstract: Trichinella can be detected in a tissue extract sample. A suitable kit includes (a) a detection carrier containing a first antibody against one or more antigens of Trichinella, and (b) (i) a second antibody against one or more antigens of Trichinella, wherein the second antibody is bound to a signal molecule, or (b) (ii) contains one or more antigens of Trichinella bound to a signal molecule, wherein the antigens of (b) (ii) are configured so as to dissolve binding of the antigens of (a) to the first antibody by competitive displacement.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: May 26, 2020
    Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    Inventors: Jana Braasch, Stefanie Ostermann, Monika Mackiewicz
  • Patent number: 10653730
    Abstract: A method for prophylaxis or treatment of a disease includes administering an an effective amount of an agent that contains cells of Lactobacillus paracasei MCC1849 (NITE BP-01633) to a subject in need of such prophylaxis or treatment. The disease can be one or more of an inflammatory disease, ulcer, food allergies, bronchial asthma, urticaria, pollinosis, anaphylactic shock or an opportunistic infection.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: May 19, 2020
    Assignee: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Tomohiro Tanaka, Noriyuki Iwabuchi, Yohei Sato, Kanetada Shimizu, Toshitaka Odamaki
  • Patent number: 10603370
    Abstract: The present invention includes compositions and methods of preparing flagellar-coiling protein 1 (Fcp1)-deficient Leptospira bacterium. In one aspect, the invention includes an isolated, flagellar-coiling protein 1 (Fcp1)-deficient Leptospira bacterium. Another aspect includes a composition comprising a flagellar-coiling protein 1 (Fcp1) deficient Leptospira bacterium. Yet another aspect includes a method of producing a motility-deficient Leptospira bacterium comprising inhibiting expression of a wild-type flagellar-coiling protein 1 (Fcp1) gene. Methods of stimulating an immune response and reducing or treating an infectious disease caused by one or more Leptospira bacteria in a subject in need thereof comprising administering a composition comprising an effective amount of flagellar-coiling protein 1 (Fcp1) deficient Leptospira bacteria to the subject are also included.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: March 31, 2020
    Assignee: Yale University
    Inventors: Albert Ko, Elsio Wunder
  • Patent number: 10597740
    Abstract: The present invention a Bifidobacterium longum CBT BG7 Bifidobacterium, which has an excellent growth promoting effect and was internationally deposited with the Korean Collection for Type Culture (KCTC) of the Korea Research Institute of Bioscience and Biotechnology under accession number KCTC 12200BP. The strain of the present invention has a beneficial effect of promoting growth by promoting the digestion of human milk oligosaccharides to enhance immunity together with physical strength.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: March 24, 2020
    Assignee: CELL BIOTECH CO., LTD.
    Inventor: Myung Jun Chung
  • Patent number: 10598660
    Abstract: The present invention relates to use of an Anaplasma phagocytophilum protein APH1384 as diagnostic antigen for granulocytic anaplasmosis. The protein can remedy the drawback of missed detection of an existing diagnostic antigen P44 for granulocytic anaplasmosis, improve sensitivity of detection for granulocytic anaplasmosis, and facilitate rapid and accurate clinical diagnosis of granulocytic anaplasmosis.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: March 24, 2020
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Hua Niu, Meiling He, Shuyan Wu
  • Patent number: 10588926
    Abstract: A novel lactic acid Lactobacillus rhamnosus bacterium suitable for treatment of e.g. bacterial vaginosis.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 17, 2020
    Assignee: FERRING B.V.
    Inventors: Maria Empar Chenoll Cuadros, Beatriz Casinos Ramo, Angela Silva Angulo, Daniel Ramon Vidal, Salvador Genoves Martinez
  • Patent number: 10590426
    Abstract: Described herein are mutant cyanobacterial cell populations that have a smaller mean cell length than wild type cyanobacterial cell populations of the same species.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: March 17, 2020
    Assignee: Board of Trustees of Michigan State University
    Inventors: Daniel Christopher Ducat, Katherine Osteryoung, Joshua Scott MacCready
  • Patent number: 10583187
    Abstract: The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: March 10, 2020
    Assignee: Pfizer Inc.
    Inventors: Jianxin Gu, Jin-hwan Kim, Avvari Krishna Prasad, Yu-ying Yang
  • Patent number: 10576138
    Abstract: Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: March 3, 2020
    Assignee: Bharat Biotech International Ltd.
    Inventors: Krishna Murthy Ella, Venkatesan Ramasamy, Mandalapu Gangadhara Naidu
  • Patent number: 10563168
    Abstract: This disclosure describes modified photosynthetic microorganisms, including Cyanobacteria that have a reduced amount of a light harvesting protein (LHP) and contain one or more introduced or overexpressed polynucleotides encoding one or more enzymes associated with lipid biosynthesis, and which are capable of producing increased amounts of fatty acids and/or synthesizing triglycerides.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: February 18, 2020
    Assignee: LUMEN BIOSCIENCE, INC.
    Inventors: James Roberts, Michael Carleton, Damian Carrieri, Jason W. Hickman
  • Patent number: 10555992
    Abstract: Described are immunogenic proteins against Clostridium difficile. Also described are compositions comprising the immunogenic proteins. Further described are methods of preventing or treating a Clostridium difficile infection in a subject in need thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: February 11, 2020
    Assignee: University of South Florida
    Inventor: Xingmin Sun
  • Patent number: 10550175
    Abstract: An object of the present invention is to provide a detection marker that can simply and rapidly detect Mycoplasma pneumoniae, which is a pathogen of mycoplasma pneumonia, at a high sensitivity, a specific antibody against the marker, and also an immunological detection method and a kit containing the antibody. Infection with Mycoplasma pneumoniae can be rapidly and specifically diagnosed by producing an antibody specifically reactive to P30 protein of Mycoplasma pneumoniae and performing an immunological assay using the P30 protein as a detection marker. The present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the bacteria at a hospital or the like without need of specialized instruments or skilled techniques.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: February 4, 2020
    Assignee: TAUNS CO., LTD.
    Inventor: Kenji Saito
  • Patent number: 10538733
    Abstract: A cell, isolated nucleic acid, vector, isolated polypeptide, and method of treating a bacterial infection are provided. The cell includes a modified Acinetobacter baumannii cell having a mutation in an A. baumannii gene selected from a mutation that occurs when generating mutations in A. baumanni using transposon mutagenesis. The isolated nucleic acid includes a sequence expressing a lpsB, mffT, or GctA polypeptide comprising at least one nucleic acid mutation. The vector includes the isolated nucleic acid. The isolated polypeptide includes a lpsB, mffT, or GctA polypeptide comprising at least one nucleic acid mutation. The method of treating a bacterial infection includes administering to a subject an effective amount of an Acinetobacter baumannii composition including modified Acinetobacter baumannii cell.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: January 21, 2020
    Assignee: Vanderbilt University
    Inventors: Eric P. Skaar, M. Indriati Hood, Michael Noto
  • Patent number: 10525112
    Abstract: A method for treating an abnormality of the first metatarsophalangeal joint of the foot of a mammal includes electrically stimulating a site on each of the extensor hallucis brevis and adductor hallucis muscles of a foot of the mammal affected by the abnormality, and visually confirming that the stimulated muscles responds to the stimulation by contracting. An amount of botulinum toxin effective to treat the abnormality is then injected to the confirmed sites on the extensor hallucis brevis and the adductor hallucis muscles of the affected foot.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: January 7, 2020
    Inventor: Philip Andrew Radovic
  • Patent number: 10525126
    Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: January 7, 2020
    Assignees: THE TRUSTEES OF PRINCETON UNIVERSITY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Thomas J. Silhavy, Marcin Grabowicz, Daniel Kahne, Matthew Lebar, Dorothee Andres